Weekly News Round-up – 21/2/20

Fascinating news this week as scientists at MIT found the first strong antibiotics devised entirely by machine learning algorithm. The resulting medicines have so far proven highly effective against ‘critical’ pathogens. The scientists are now intending to search for more...

4 days ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

Weekly News Round-up – 21/2/20

Fascinating news this week as scientists at MIT found the first strong antibiotics devised entirely by machine learning algorithm. The resulting medicines have so far proven highly effective against ‘critical’ pathogens. The scientists are now intending to search for more...

4 days ago

The Changing Role of the Blockbuster Drug

There are few pharmaceutical companies not seeking the next big "blockbuster", a market drug earning revenue over $1 billion. These big-name products, which include Keytruda and Lipitor, are well-marketed and broadly-effective, often across several illnesses. For years scientists have worked...

2 weeks ago
Oncology,R&D,Biology,News

The Changing Role of the Blockbuster Drug

There are few pharmaceutical companies not seeking the next big "blockbuster", a market drug earning revenue over $1 billion. These big-name products, which include Keytruda and Lipitor, are well-marketed and broadly-effective, often across several illnesses. For years scientists have worked...

2 weeks ago

Weekly News Round-up – 31/1/20

With the Chinese Coronavirus dominating the news this week, headlines were a diverse affair: Novartis has backed out of a generic program copying Advair, with the company citing that they could no longer see a way to launch in the...

4 weeks ago
R&D,Bioprocess,Weekly Roundups

Weekly News Round-up – 31/1/20

With the Chinese Coronavirus dominating the news this week, headlines were a diverse affair: Novartis has backed out of a generic program copying Advair, with the company citing that they could no longer see a way to launch in the...

4 weeks ago

How Can We Speed up Vaccine R&D?

With the rapid spread of the coronavirus 2019-nCoV through China and now globally, governments and organisations have implemented a range of preventative measures. Chinese provinces including Beijing and Shanghai have shut down long-distance bus services and entirely closed off some...

4 weeks ago
R&D,Biology,News

How Can We Speed up Vaccine R&D?

With the rapid spread of the coronavirus 2019-nCoV through China and now globally, governments and organisations have implemented a range of preventative measures. Chinese provinces including Beijing and Shanghai have shut down long-distance bus services and entirely closed off some...

4 weeks ago

Antibiotic Resistance: Is Pharma Doing Enough?

Developed resistances to certain antibiotics have occurred since their creation in the 1940s. Scientists found the first case of resistance just four years after antibiotics entered mass production. Only recently, however, has the issue taken a critical turn. Resistant strains of...

1 month ago
R&D,Pharmacovigilance,Biology

Antibiotic Resistance: Is Pharma Doing Enough?

Developed resistances to certain antibiotics have occurred since their creation in the 1940s. Scientists found the first case of resistance just four years after antibiotics entered mass production. Only recently, however, has the issue taken a critical turn. Resistant strains of...

1 month ago

Avoiding Bias in Precision Medicine

Precision medicine, or the tailoring of healthcare towards either a select group or individual based on their needs and physiology instead of their illness, is a well-known and highly-anticipated aspect of healthcare pharmaceuticals, with thousands of articles written on it. ...

1 month ago
R&D,Clinical Development,Clinical Operations,Race and Ethics,Precision and Personalised Medicine,News

Avoiding Bias in Precision Medicine

Precision medicine, or the tailoring of healthcare towards either a select group or individual based on their needs and physiology instead of their illness, is a well-known and highly-anticipated aspect of healthcare pharmaceuticals, with thousands of articles written on it. ...

1 month ago

Proventa’s Weekly Round-up – 10/1/19

Happy new year! It’s a fairly slow week as the sector takes stock and begins to get back, with annual price rises the main event in the news - big pharma has announced its regular price increases for the new...

2 months ago
R&D,Bioprocess,Weekly Roundups

Proventa’s Weekly Round-up – 10/1/19

Happy new year! It’s a fairly slow week as the sector takes stock and begins to get back, with annual price rises the main event in the news - big pharma has announced its regular price increases for the new...

2 months ago

The Future of Organ-on-a-Chip

Dozens of solutions have been suggested to lessen the crisis that has been hitting pharma R&D recently. Over the last decade, the cost of creating drugs has skyrocketed even as the amount of new medicines reaching market is steadily declining....

2 months ago
Oncology,R&D,Biology,News

The Future of Organ-on-a-Chip

Dozens of solutions have been suggested to lessen the crisis that has been hitting pharma R&D recently. Over the last decade, the cost of creating drugs has skyrocketed even as the amount of new medicines reaching market is steadily declining....

2 months ago

AI and Pharmacovigilance ADR processing

Many of the problems that have long been inherent in Pharmacovigilance (PV) - such as historic limitations in the information that is published in case reports, analysis of electronic health records and integration - have found an answer in the...

5 months ago
R&D,Pharmacovigilance,Bioinformatics

AI and Pharmacovigilance ADR processing

Many of the problems that have long been inherent in Pharmacovigilance (PV) - such as historic limitations in the information that is published in case reports, analysis of electronic health records and integration - have found an answer in the...

5 months ago

The Abbvie-Allergan Deal: A Matter of Distrust?

Compared to the merger announcement itself, the industry reaction to the $63 billion Abbvie buyout of Allergan, announced this June, was no big surprise. Abbvie, seeking to replace its now-ageing blockbuster drug Humira, was the only suitor for the Botox...

5 months ago
Pharmacovigilance,News

The Abbvie-Allergan Deal: A Matter of Distrust?

Compared to the merger announcement itself, the industry reaction to the $63 billion Abbvie buyout of Allergan, announced this June, was no big surprise. Abbvie, seeking to replace its now-ageing blockbuster drug Humira, was the only suitor for the Botox...

5 months ago